Back to search
C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which C9ORF72 Amyotrophic Lateral Sclerosis (ALS) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which C9ORF72 Amyotrophic Lateral Sclerosis (ALS) trials you may qualify forPre-fALS is a prospective natural history and biomarker study of people not yet affected with ALS, but who are at genetic risk for developing ALS. The investiga…
Individuals with Amyotrophic Lateral Sclerosis (ALS) carrying the C9orf72 HRE mutation (C9Pos) often exhibit different phenotypic traits compared to other patie…
This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron…
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEF…
Background: \- Some people have a mutation in the C9ORF72 gene that causes amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). The mutation c…
Background: Amyotrophic lateral sclerosis (ALS) is a disorder that damages nerve cells in the brain and spinal cord. It can cause muscle weakness, paralysis, a…
This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementi…